Evidence map›Paper›PMID 25177796›Full record

ArticleThe Biochemical journal2014

Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase.

Ruzica Bago, Nazma Malik, Michael J Munson, Alan R Prescott, Paul Davies, Eeva Sommer, Natalia Shpiro, Richard Ward, Darren Cross, Ian G Ganley and 1 more

Open access · hybridAbstract read
In one paragraph

Article in The Biochemical journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 204 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
204citing papers in PubMed, 1 pooled it
10.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

204 citing papers in PubMed, 1 synthesis or guideline pooled it, 313 citations in OpenAlex.

  1. Guideline
  2. Autophagy modulation in cancer.Nature reviews. Drug discovery · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. A renaissance in targeting the PI3K/AKT/mTOR pathway.Nature reviews. Drug discovery · 2026
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

144 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Ruzica Bago*MRC Protein Phosphorylation and Ubiquitylation Unit, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.
Nazma Malik*MRC Protein Phosphorylation and Ubiquitylation Unit, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.
Michael J Munson*MRC Protein Phosphorylation and Ubiquitylation Unit, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.
Alan R Prescott†Division of Cell Signalling and Immunology, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.
Paul Davies*MRC Protein Phosphorylation and Ubiquitylation Unit, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.
Eeva Sommer*MRC Protein Phosphorylation and Ubiquitylation Unit, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.
Natalia Shpiro*MRC Protein Phosphorylation and Ubiquitylation Unit, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.
Richard Ward‡Oncology iMED, AstraZeneca, Alderley Park, Cheshire SK10 4TG, U.K.
Darren Cross‡Oncology iMED, AstraZeneca, Alderley Park, Cheshire SK10 4TG, U.K.
Ian G Ganley*MRC Protein Phosphorylation and Ubiquitylation Unit, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.
Dario R Alessi*MRC Protein Phosphorylation and Ubiquitylation Unit, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.
MRC Protein Phosphorylation and Ubiquitylation Unit · GBAstraZeneca (United Kingdom) · GBUniversity of Dundee · GB

Funding

Medical Research Council MC_G1000735Medical Research Council MC_UP_A500_1019Medical Research Council MC_UU_12016/2Medical Research Council MC_UU_12016/4Wellcome Trust 089698Wellcome Trust 097945/B/11/Z
6 · The paper itself

Abstract

The Vps34 (vacuolar protein sorting 34) class III PI3K (phosphoinositide 3-kinase) phosphorylates PtdIns (phosphatidylinositol) at endosomal membranes to generate PtdIns(3)P that regulates membrane trafficking processes via its ability to recruit a subset of proteins possessing PtdIns(3)P-binding PX (phox homology) and FYVE domains. In the present study, we describe a highly selective and potent inhibitor of Vps34, termed VPS34-IN1, that inhibits Vps34 with 25 nM IC50 in vitro, but does not significantly inhibit the activity of 340 protein kinases or 25 lipid kinases tested that include all isoforms of class I as well as class II PI3Ks. Administration of VPS34-IN1 to cells induces a rapid dose-dependent dispersal of a specific PtdIns(3)P-binding probe from endosome membranes, within 1 min, without affecting the ability of class I PI3K to regulate Akt. Moreover, we explored whether SGK3 (serum- and glucocorticoid-regulated kinase-3), the only protein kinase known to interact specifically with PtdIns(3)P via its N-terminal PX domain, might be controlled by Vps34. Mutations disrupting PtdIns(3)P binding ablated SGK3 kinase activity by suppressing phosphorylation of the T-loop [PDK1 (phosphoinositide-dependent kinase 1) site] and hydrophobic motif (mammalian target of rapamycin site) residues. VPS34-IN1 induced a rapid ~50-60% loss of SGK3 phosphorylation within 1 min. VPS34-IN1 did not inhibit activity of the SGK2 isoform that does not possess a PtdIns(3)P-binding PX domain. Furthermore, class I PI3K inhibitors (GDC-0941 and BKM120) that do not inhibit Vps34 suppressed SGK3 activity by ~40%. Combining VPS34-IN1 and GDC-0941 reduced SGK3 activity ~80-90%. These data suggest SGK3 phosphorylation and hence activity is controlled by two pools of PtdIns(3)P. The first is produced through phosphorylation of PtdIns by Vps34 at the endosome. The second is due to the conversion of class I PI3K product, PtdIns(3,4,5)P3 into PtdIns(3)P, via the sequential actions of the PtdIns 5-phosphatases [SHIP1/2 (Src homology 2-domain-containing inositol phosphatase 1/2)] and PtdIns 4-phosphatase [INPP4B (inositol polyphosphate 4-phosphatase type II)]. VPS34-IN1 will be a useful probe to delineate physiological roles of the Vps34. Monitoring SGK3 phosphorylation and activity could be employed as a biomarker of Vps34 activity, in an analogous manner by which Akt is used to probe cellular class I PI3K activity. Combining class I (GDC-0941) and class III (VPS34-IN1) PI3K inhibitors could be used as a strategy to better analyse the roles and regulation of the elusive class II PI3K.

Indexed as

Amino Acid MotifsAminopyridinesCell LineClass III Phosphatidylinositol 3-KinasesClass II Phosphatidylinositol 3-KinasesClass I Phosphatidylinositol 3-KinasesEndosomesHumansHydrophobic and Hydrophilic InteractionsInositol Polyphosphate 5-PhosphatasesPhosphatidylinositol-3,4,5-Trisphosphate 5-PhosphatasesPhosphatidylinositol PhosphatesPhosphoinositide-3 Kinase InhibitorsPhosphoric Monoester HydrolasesPhosphorylationProtein Binding1-((2-((2-chloropyridin-4yl)amino)-4'-(cyclopropylmethyl)-(4,5'-bipyrimidin)-2'-yl)amino)-2-methylpropan-2-olAminopyridinesClass III Phosphatidylinositol 3-KinasesClass II Phosphatidylinositol 3-KinasesClass I Phosphatidylinositol 3-KinasesInositol Polyphosphate 5-PhosphatasesINPP5D protein, humanINPPL1 protein, humanPhosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatasesphosphatidylinositol-3,4-bisphosphate 4-phosphatasePhosphatidylinositol PhosphatesPhosphoinositide-3 Kinase InhibitorsPhosphoric Monoester HydrolasesProtein Serine-Threonine KinasesPyrimidinesSerum-Glucocorticoid Regulated KinasesSGK3 protein, human

Identifiers

PMID25177796
PMCPMC4209782
OpenAlexW2162889213

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.